Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy

Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape for the treatment of multiple types of cancer. However, only a subpopulation of patients has obvious tumor response and long-term survival afte...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic Advances in Medical Oncology Vol. 15; p. 17588359231163807
Main Authors Zheng, Lin-Peng, Yang, Jing, Chen, Xie-Wan, Li, Ling-Chen, Sun, Jian-Guo
Format Book Review Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2023
Sage Publications Ltd
SAGE Publishing
Subjects
Artificial intelligence
Biomarkers
Cancer
Cancer immunotherapy
Genomic Biomarkers in Cancer Immunotherapy
Immune checkpoint inhibitors
Malignancy
Patients
Peripheral blood
Solid tumors
Toxicity
Tumor microenvironment
pseudoprogression
immune checkpoint inhibitors
biomarker
immune-related adverse events
hyperprogressive disease
Online AccessGet full text

Cover

Abstract Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape for the treatment of multiple types of cancer. However, only a subpopulation of patients has obvious tumor response and long-term survival after ICIs treatment, and many patients may experience other undesirable clinical features. Therefore, biomarkers are critical for patients to choose exact optimum therapy. Here, we reviewed existing preclinical and clinical biomarkers of immunotherapeutic efficacy and immune-related adverse events (irAEs). Based on efficacy prediction, pseudoprogression, hyperprogressive disease, or irAEs, these biomarkers were divided into cancer cell-derived biomarkers, tumor microenvironment-derived biomarkers, host-derived biomarkers, peripheral blood biomarkers, and multi-modal model and artificial intelligence assessment-based biomarkers. Furthermore, we describe the relation between ICIs efficacy and irAEs. This review provides the overall perspective of biomarkers of immunotherapeutic outcome and irAEs prediction during ICIs treatment.
AbstractList Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape for the treatment of multiple types of cancer. However, only a subpopulation of patients has obvious tumor response and long-term survival after ICIs treatment, and many patients may experience other undesirable clinical features. Therefore, biomarkers are critical for patients to choose exact optimum therapy. Here, we reviewed existing preclinical and clinical biomarkers of immunotherapeutic efficacy and immune-related adverse events (irAEs). Based on efficacy prediction, pseudoprogression, hyperprogressive disease, or irAEs, these biomarkers were divided into cancer cell-derived biomarkers, tumor microenvironment-derived biomarkers, host-derived biomarkers, peripheral blood biomarkers, and multi-modal model and artificial intelligence assessment-based biomarkers. Furthermore, we describe the relation between ICIs efficacy and irAEs. This review provides the overall perspective of biomarkers of immunotherapeutic outcome and irAEs prediction during ICIs treatment.
Author Yang, Jing
Li, Ling-Chen
Chen, Xie-Wan
Sun, Jian-Guo
Zheng, Lin-Peng
Author_xml – sequence: 1
  givenname: Lin-Peng
  surname: Zheng
  fullname: Zheng, Lin-Peng
  organization: Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China
– sequence: 2
  givenname: Jing
  surname: Yang
  fullname: Yang, Jing
  organization: Department of Thoracic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
– sequence: 3
  givenname: Xie-Wan
  surname: Chen
  fullname: Chen, Xie-Wan
  organization: Department of Basic Medicine, Army Medical University, Chongqing, China
– sequence: 4
  givenname: Ling-Chen
  surname: Li
  fullname: Li, Ling-Chen
  email: sunjg09@aliyun.com
  organization: Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China
– sequence: 5
  givenname: Jian-Guo
  surname: Sun
  fullname: Sun, Jian-Guo
  email: sunjg09@aliyun.com
  organization: Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37113734$$D View this record in MEDLINE/PubMed
BookMark eNp1kk2PFCEQholZ437oD_BiOvHiZVZoaD5OxkzcdZNNvOiZAF3MMHbDCN3q_HuZnXXc1XgCXt56qgrqHJ3EFAGhlwRfEiLEWyI6KWmnWkoIpxKLJ-hsry324smD_Sk6L2WDMeeM42folApCqKDsDMEy5QyDmUKKTfLNNoMbQgzODI2JfXM82JBGk79CLs2PMK0b8L7qbnfnmtLP4MK02xOciQ5yE8ZxjmlaQzbb3XP01JuhwIv79QJ9ufrweflxcfvp-mb5_nbhmOymhWWKeiEVlt7x3knre0UIeOiZr6Vb0VHf9WAsk7wDirEFRpknymMrpJD0At0cuH0yG73NoZa808kEfSekvNImT8ENoKFtlaIM1wyCUessEGV4hzF2kkriKuvdgbWd7Qi9gzhlMzyCPr6JYa1X6bsmmLScc1wJb-4JOX2boUx6DMXBMJgIaS66rT-mCO5EW62v_7Ju0pxjfSvdqhZ3TBFJqoscXC6nUjL4YzUE6_1E6H8mosa8etjGMeL3CFTD5cFQzAr-pP0_8RehOMDz
Cites_doi 10.1016/j.jdermsci.2016.12.019
10.1001/jamaoncol.2017.0013
10.1200/JCO.2022.40.16_suppl.2558
10.1002/cam4.1356
10.1016/j.cllc.2019.08.006
10.1056/NEJMc1713444
10.1007/s10637-017-0524-2
10.2967/jnmt.117.204933
10.1158/1078-0432.CCR-16-0127
10.1093/annonc/mdy014
10.1016/S1470-2045(21)00582-9
10.1200/JCO.2022.40.16_suppl.2598
10.1200/JCO.2022.40.16_suppl.9048
10.1038/s41598-019-49771-0
10.18632/oncotarget.24509
10.1016/j.tranon.2022.101375
10.1038/ng.3202
10.1016/j.annonc.2020.01.006
10.3390/cancers13020286
10.18632/oncotarget.27563
10.1016/j.lungcan.2020.08.015
10.1056/NEJMra1703481
10.1200/JCO.18.01042
10.1155/2021/6639366
10.1200/JCO.2022.40.16_suppl.9064
10.1136/jitc-2020-001935
10.1158/2159-8290.CD-17-0226
10.1200/JCO.2022.40.16_suppl.2626
10.1016/j.jtho.2016.10.015
10.1200/JCO.2018.79.0006
10.1016/j.cllc.2016.03.003
10.1093/annonc/mdx108
10.3389/fimmu.2021.665133
10.1136/jitc-2021-002797
10.1126/science.aao4572
10.1038/s41591-018-0101-z
10.18632/oncotarget.20346
10.1056/NEJMoa1801946
10.1056/NEJMoa1501824
10.1158/1078-0432.CCR-15-1678
10.2147/OTT.S153290
10.1001/jamaoncol.2015.2151
10.1002/ctm2.167
10.1186/s12885-020-07727-y
10.1186/s40425-015-0081-1
10.1016/j.annonc.2021.08.1744
10.1186/s12967-018-1467-x
10.1038/s41467-020-18742-9
10.1016/S1470-2045(17)30065-7
10.18632/oncotarget.12677
10.1038/s41416-018-0074-1
10.3389/fimmu.2021.786046
10.1016/S1470-2045(16)30624-6
10.21037/tlcr-21-156
10.1159/000512633
10.1101/gr.219915.116
10.1038/s41598-021-88307-3
10.1016/j.lungcan.2019.02.009
10.1111/cei.13505
10.1111/1759-7714.13594
10.1038/s41571-021-00564-3
10.1186/s40425-019-0650-9
10.1016/j.ctrv.2020.102134
10.1200/JCO.2022.40.16_suppl.2662
10.1001/jamaoncol.2017.4771
10.1093/jnci/djv303
10.18632/oncotarget.16935
10.1056/NEJMoa1412082
10.1016/j.cell.2016.02.065
10.1016/j.biopha.2022.112949
10.1093/annonc/mdx190
10.2967/jnumed.119.237768
10.1016/j.ejca.2018.04.005
10.1001/jamaoncol.2018.5860
10.1038/s41416-018-0155-1
10.1371/journal.pone.0015661
10.1172/JCI96798
10.1158/2326-6066.CIR-20-0196
10.21037/tlcr-22-171
10.1038/nature21349
10.1016/j.jtho.2019.01.011
10.1016/S0140-6736(16)00587-0
10.1200/JCO.2022.40.16_suppl.2549
10.1002/ijc.31923
10.1007/s00262-020-02716-3
10.1038/nature13954
10.1126/science.aan6733
10.1200/JCO.2022.40.16_suppl.2550
10.1200/JCO.2022.40.16_suppl.2544
10.1158/1078-0432.CCR-17-0231
10.1038/s41416-020-0975-7
10.1200/JCO.2022.40.16_suppl.9066
10.21037/tlcr-21-575
10.1186/s40425-017-0300-z
10.2147/OTT.S228138
10.1186/s12916-020-01549-2
10.1158/1078-0432.CCR-16-3133
10.1038/s41598-019-50574-6
10.1016/j.jtho.2021.07.009
10.1200/JCO.2022.40.16_suppl.2596
10.1038/nature11252
10.1159/000438523
10.1016/S1470-2045(18)30608-9
10.7326/M17-2073
10.2337/dbi18-0002
10.1080/15384047.2016.1156256
10.1126/science.aax0701
10.1001/jamaoncol.2017.5332
10.1007/s00432-020-03316-5
10.1186/s12943-020-01200-x
ContentType Book Review
Journal Article
Copyright The Author(s), 2023
The Author(s), 2023.
The Author(s), 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2023 2023 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2023
– notice: The Author(s), 2023.
– notice: The Author(s), 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2023 2023 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1177/17588359231163807
DatabaseName SAGE Open Access
PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Access via ProQuest (Open Access)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: SAGE Open Access
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: 7X7
  name: ProQuest_Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1758-8359
EndPage 17588359231163807
ExternalDocumentID oai_doaj_org_article_e2299340d91743bcbe19a65000c8381c
10_1177_17588359231163807
37113734
10.1177_17588359231163807
Genre Journal Article
Review
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 82172670
  funderid: https://doi.org/10.13039/501100001809
– fundername: National Natural Science Foundation of China
  grantid: 81773245
  funderid: https://doi.org/10.13039/501100001809
– fundername: National Natural Science Foundation of China
  grantid: 82202951
  funderid: https://doi.org/10.13039/501100001809
– fundername: chongqing science and technology innovation leading talent support program
  grantid: cstccxljrc201910
  funderid: https://doi.org/10.13039/501100019071
– fundername: National Natural Science Foundation of China
  grantid: 81972858
  funderid: https://doi.org/10.13039/501100001809
– fundername: Cultivation Program for Clinical Research Talents of Army Medical University
  grantid: 2018XLC1010
– fundername: Technology Innovation for Youth in Army Medical University
  grantid: 2019XQN10
– fundername: ;
  grantid: cstccxljrc201910
– fundername: ;
  grantid: 81972858
– fundername: ;
  grantid: 82172670
– fundername: ;
  grantid: 81773245
– fundername: ;
  grantid: 82202951
– fundername: ;
  grantid: 2019XQN10
– fundername: ;
  grantid: 2018XLC1010
GroupedDBID ---
-MK
-TM
01A
0R~
29Q
31X
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AADTT
AADUE
AAJQC
AAQDB
AARDL
AARIX
AATBZ
ABAFQ
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACGZU
ACOFE
ACROE
ACSBE
ACSIQ
ACUIR
ADBBV
ADOGD
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEUIJ
AEWDL
AEWHI
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AGNHF
AHHFK
AJUZI
ALIPV
ALJHS
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B8M
B8Z
BAWUL
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
COF
DC-
DC.
DIK
DOPDO
DV7
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
HF~
HMCUK
HVGLF
HYE
HZ~
J8X
JCYGO
K.F
M4V
N9A
O9-
OK1
P.B
PIMPY
PQQKQ
ROL
RPM
S01
SFC
SGV
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
H13
NPM
AAYXX
CITATION
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c485t-b493f78908fc6dc8bfd911efed4f664b753f5deab4865e300be434f19f0b78783
IEDL.DBID RPM
ISSN 1758-8359
1758-8340
IngestDate Tue Oct 22 15:14:32 EDT 2024
Tue Sep 17 21:30:59 EDT 2024
Sat Oct 05 05:22:03 EDT 2024
Fri Nov 08 20:54:38 EST 2024
Wed Oct 09 16:52:36 EDT 2024
Sat Sep 28 08:20:51 EDT 2024
Tue Jul 16 20:50:59 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords pseudoprogression
immune checkpoint inhibitors
biomarker
immune-related adverse events
hyperprogressive disease
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The Author(s), 2023.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c485t-b493f78908fc6dc8bfd911efed4f664b753f5deab4865e300be434f19f0b78783
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Lin-Peng Zheng and Jing-Yang contributed equally to this study.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126660/
PMID 37113734
PQID 2920549181
PQPubID 4450840
ParticipantIDs doaj_primary_oai_doaj_org_article_e2299340d91743bcbe19a65000c8381c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10126660
proquest_miscellaneous_2807910572
proquest_journals_2920549181
crossref_primary_10_1177_17588359231163807
pubmed_primary_37113734
sage_journals_10_1177_17588359231163807
PublicationCentury 2000
PublicationDate 2023-01-01
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-01
  day: 01
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic Advances in Medical Oncology
PublicationTitleAlternate Ther Adv Med Oncol
PublicationYear 2023
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Eshghi, Garland, Nia 2018; 46
Cao, Zhang, Zhou 2022; 11
2012; 487
Stamatouli, Quandt, Perdigoto 2018; 67
Das, Bar, Ferreira 2018; 128
Dudley, Lin, Le 2016; 22
Bins, Basak, El 2018; 118
Choi, Kim, Kim 2020; 11
Hwang, Kim, Choi 2021; 9
Lin, Vanneste, Yu 2021; 10
Kato, Goodman, Walavalkar 2017; 23
Socinski, Nishio, Jotte 2021; 16
Queirolo, Dozin, Morabito 2018; 97
Karabajakian, Garrivier, Crozes 2020; 11
Ready, Hellmann, Awad 2019; 37
Fujimura, Sato, Tanita 2018; 9
Schott, Pizon, Pachmann 2017; 8
Howitt, Shukla, Sholl 2015; 1
Geng, Shao, He 2015; 37
Naranbhai, Viard, Dean 2022; 23
Economopoulou, Anastasiou, Papaxoinis 2021; 13
Tumeh, Harview, Yearley 2014; 515
Hakozaki, Richard, Elkrief 2020; 8
Chen, Gou, Yan 2021; 2021
Andrianova, Bazykin, Nikolaev 2017; 27
Zheng, Wang, Tu 2019; 7
Zhao, Hu, Hu 2022; 150
Postow, Sidlow, Hellmann 2018; 378
Cao, Yang, Chen 2022; 20
Kim, Cristescu, Bass 2018; 24
Jeanson, Tomasini, Souquet-Bressand 2019; 14
Chen, Mellman 2017; 541
Wong, Nebhan, Johnson 2021; 12
Dall’Olio, Marabelle, Caramella 2022; 19
Sharma, Retz, Siefker-Radtke 2017; 18
Michailidou, Khaki, Morelli 2021; 11
Sanchez-Gastaldo, Munoz-Fuentes, Molina-Pinelo 2021; 10
Mezquita, Auclin, Ferrara 2018; 4
Guibert, Mazieres, Delaunay 2017; 8
Puzanov, Diab, Abdallah 2017; 5
Uruga, Bozkurtlar, Huynh 2017; 12
Asada, Mikami, Niimura 2021; 99
Petrova, Donev, Radanova 2020; 202
Timmermann, Kerick, Roehr 2010; 5
Shlien, Campbell, de Borja 2015; 47
Robert, Long, Brady 2015; 372
Colen, Fujii, Bilen 2018; 36
Castello, Rossi, Mazziotti 2020; 61
Arbour, Mezquita, Long 2018; 36
Valpione, Pasquali, Campana 2018; 16
Chalabi, Cardona, Nagarkar 2020; 31
Rosner, Kwong, Shoushtari 2018; 7
Toi, Sugawara, Sugisaka 2019; 5
Le, Durham, Smith 2017; 357
Zhou, Yao, Yang 2020; 18
Agullo-Ortuno, Gomez-Martin, Ponce 2020; 21
Fluckiger, Daillere, Sassi 2020; 369
Cortellini, Ricciuti, Facchinetti 2021; 32
Garon, Rizvi, Hui 2015; 372
Hellmann, Ciuleanu, Pluzanski 2018; 378
Tanaka, Okiyama, Okune 2017; 86
Jing, Liu, Ye 2020; 11
Hussaini, Chehade, Boldt 2021; 92
Ji, Liu, Li 2016; 17
Cortez, Ivan, Valdecanas 2016; 108
Han, Alu, Xiao 2020; 10
Schuiveling, Tonk, Verheijden 2021; 70
Salem, Manouchehri, Moey 2018; 19
Kiriu, Yamamoto, Nagano 2019; 12
Weiss, Beck, Braun 2017; 23
Yarchoan, Hopkins, Jaffee 2017; 377
Adam, Le Stang, Rouquette 2018; 29
Hugo, Zaretsky, Sun 2016; 165
Kim, Chun, Kim 2021; 21
Yang, Chen, Gu 2021; 12
Hagi, Kurokawa, Kawabata 2020; 123
Hellmann, Rizvi, Goldman 2017; 18
Wang, Sun, Zeng 2019; 9
Rimm, Han, Taube 2017; 3
Weide, Martens, Hassel 2016; 22
Eun, Kim, Sun 2019; 9
Sanmamed, Perez-Gracia, Schalper 2017; 28
Matsuo, Azuma, Hattori 2019; 144
Abdel-Wahab, Shah, Lopez-Olivo 2018; 168
Chaput, Lepage, Coutzac 2017; 28
Wang, Wang, Zhong 2020; 19
Mouw, Goldberg, Konstantinopoulos 2017; 7
Jiang, Bai, Zhou 2019; 130
Lee, Long, Menzies 2018; 4
Kalinich, Murphy, Wongvibulsin 2021; 9
Sacdalan, Lucero, Sacdalan 2018; 11
Planchard, Yokoi, McCleod 2016; 17
Khan, Khan, Luo 2019; 120
Tarhini, Zahoor, Lin 2015; 3
Chowell, Morris, Grigg 2018; 359
Nakamura, Kitano, Takahashi 2016; 7
Chu, Zhao, Zhou 2020; 150
Fehrenbacher, Spira, Ballinger 2016; 387
Park, Chun, Lee 2020; 146
bibr50-17588359231163807
bibr35-17588359231163807
bibr106-17588359231163807
bibr48-17588359231163807
bibr22-17588359231163807
bibr105-17588359231163807
bibr75-17588359231163807
bibr91-17588359231163807
bibr88-17588359231163807
bibr51-17588359231163807
bibr107-17588359231163807
bibr11-17588359231163807
bibr21-17588359231163807
bibr37-17588359231163807
bibr47-17588359231163807
bibr87-17588359231163807
bibr77-17588359231163807
bibr36-17588359231163807
bibr20-17588359231163807
bibr10-17588359231163807
bibr80-17588359231163807
bibr46-17588359231163807
bibr76-17588359231163807
bibr90-17588359231163807
bibr86-17588359231163807
bibr99-17588359231163807
bibr60-17588359231163807
bibr40-17588359231163807
bibr8-17588359231163807
bibr32-17588359231163807
bibr103-17588359231163807
bibr110-17588359231163807
bibr12-17588359231163807
bibr52-17588359231163807
bibr94-17588359231163807
bibr17-17588359231163807
bibr1-17588359231163807
bibr24-17588359231163807
bibr54-17588359231163807
bibr92-17588359231163807
bibr34-17588359231163807
bibr44-17588359231163807
bibr64-17588359231163807
bibr74-17588359231163807
bibr82-17588359231163807
bibr72-17588359231163807
bibr62-17588359231163807
bibr49-17588359231163807
bibr19-17588359231163807
bibr3-17588359231163807
Grohe C (bibr45-17588359231163807) 2022
bibr69-17588359231163807
bibr79-17588359231163807
bibr89-17588359231163807
bibr59-17588359231163807
bibr29-17588359231163807
bibr39-17588359231163807
bibr100-17588359231163807
bibr96-17588359231163807
bibr28-17588359231163807
bibr15-17588359231163807
bibr42-17588359231163807
bibr5-17588359231163807
bibr4-17588359231163807
bibr55-17588359231163807
bibr84-17588359231163807
bibr68-17588359231163807
bibr71-17588359231163807
bibr14-17588359231163807
bibr112-17588359231163807
bibr57-17588359231163807
bibr31-17588359231163807
bibr67-17588359231163807
bibr41-17588359231163807
bibr95-17588359231163807
bibr27-17588359231163807
bibr97-17588359231163807
bibr26-17588359231163807
bibr111-17588359231163807
bibr101-17588359231163807
bibr30-17588359231163807
bibr6-17588359231163807
bibr16-17588359231163807
bibr70-17588359231163807
bibr66-17588359231163807
bibr56-17588359231163807
bibr73-17588359231163807
bibr2-17588359231163807
bibr18-17588359231163807
bibr38-17588359231163807
bibr109-17588359231163807
bibr25-17588359231163807
bibr65-17588359231163807
bibr81-17588359231163807
bibr102-17588359231163807
bibr98-17588359231163807
bibr7-17588359231163807
bibr58-17588359231163807
bibr85-17588359231163807
bibr61-17588359231163807
bibr78-17588359231163807
bibr9-17588359231163807
bibr104-17588359231163807
bibr13-17588359231163807
bibr23-17588359231163807
Ghasemi Saghand P (bibr108-17588359231163807) 2022
bibr43-17588359231163807
bibr33-17588359231163807
bibr53-17588359231163807
bibr63-17588359231163807
bibr93-17588359231163807
bibr83-17588359231163807
References_xml – volume: 165
  start-page: 35
  year: 2016
  end-page: 44
  article-title: Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
  publication-title: Cell
  contributor:
    fullname: Sun
– volume: 11
  start-page: 4946
  year: 2020
  article-title: Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
  publication-title: Nat Commun
  contributor:
    fullname: Ye
– volume: 372
  start-page: 2018
  year: 2015
  end-page: 2028
  article-title: Pembrolizumab for the treatment of non-small-cell lung cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Hui
– volume: 17
  start-page: 232
  year: 2016
  end-page: 236
  article-title: A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study
  publication-title: Clin Lung Cancer
  contributor:
    fullname: McCleod
– volume: 23
  start-page: 5074
  year: 2017
  end-page: 5081
  article-title: Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Braun
– volume: 150
  start-page: 112949
  year: 2022
  article-title: Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
  publication-title: Biomed Pharmacother
  contributor:
    fullname: Hu
– volume: 372
  start-page: 320
  year: 2015
  end-page: 330
  article-title: Nivolumab in previously untreated melanoma without BRAF mutation
  publication-title: N Engl J Med
  contributor:
    fullname: Brady
– volume: 118
  start-page: 1296
  year: 2018
  end-page: 1301
  article-title: Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
  publication-title: Br J Cancer
  contributor:
    fullname: El
– volume: 21
  start-page: 19
  year: 2021
  article-title: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
  publication-title: BMC Cancer
  contributor:
    fullname: Kim
– volume: 14
  start-page: 1095
  year: 2019
  end-page: 1101
  article-title: Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)
  publication-title: J Thorac Oncol
  contributor:
    fullname: Souquet-Bressand
– volume: 28
  start-page: 1368
  year: 2017
  end-page: 1379
  article-title: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
  publication-title: Ann Oncol
  contributor:
    fullname: Coutzac
– volume: 70
  start-page: 1491
  year: 2021
  end-page: 1496
  article-title: Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Verheijden
– volume: 5
  year: 2010
  article-title: Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis
  publication-title: PLoS One
  contributor:
    fullname: Roehr
– volume: 11
  start-page: 607
  year: 2022
  end-page: 616
  article-title: A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
  publication-title: Transl Lung Cancer Res
  contributor:
    fullname: Zhou
– volume: 10
  start-page: 3276
  year: 2021
  end-page: 3291
  article-title: Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review
  publication-title: Transl Lung Cancer Res
  contributor:
    fullname: Yu
– volume: 18
  start-page: 87
  year: 2020
  article-title: Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
  publication-title: BMC Med
  contributor:
    fullname: Yang
– volume: 108
  year: 2016
  article-title: PDL1 regulation by p53 via miR-34
  publication-title: J Natl Cancer Inst
  contributor:
    fullname: Valdecanas
– volume: 377
  start-page: 2500
  year: 2017
  end-page: 2501
  article-title: Tumor mutational burden and response rate to PD-1 inhibition
  publication-title: N Engl J Med
  contributor:
    fullname: Jaffee
– volume: 1
  start-page: 1319
  year: 2015
  end-page: 1323
  article-title: Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1
  publication-title: JAMA Oncol
  contributor:
    fullname: Sholl
– volume: 19
  start-page: 81
  year: 2020
  article-title: The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
  publication-title: Mol Cancer
  contributor:
    fullname: Zhong
– volume: 4
  start-page: 351
  year: 2018
  end-page: 357
  article-title: Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer
  publication-title: JAMA Oncol
  contributor:
    fullname: Ferrara
– volume: 202
  start-page: 353
  year: 2020
  end-page: 362
  article-title: Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Radanova
– volume: 146
  start-page: 3359
  year: 2020
  end-page: 3369
  article-title: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12
  publication-title: J Cancer Res Clin Oncol
  contributor:
    fullname: Lee
– volume: 24
  start-page: 1449
  year: 2018
  end-page: 1458
  article-title: Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
  publication-title: Nat Med
  contributor:
    fullname: Bass
– volume: 36
  start-page: 2872
  year: 2018
  end-page: 2878
  article-title: Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Long
– volume: 9
  year: 2021
  article-title: Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
  publication-title: J Immunother Cancer
  contributor:
    fullname: Wongvibulsin
– volume: 359
  start-page: 582
  year: 2018
  end-page: 587
  article-title: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
  publication-title: Science
  contributor:
    fullname: Grigg
– volume: 130
  start-page: 76
  year: 2019
  end-page: 83
  article-title: Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
  publication-title: Lung Cancer
  contributor:
    fullname: Zhou
– volume: 61
  start-page: 821
  year: 2020
  end-page: 826
  article-title: Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of (18)F-FDG PET/CT
  publication-title: J Nucl Med
  contributor:
    fullname: Mazziotti
– volume: 18
  start-page: 312
  year: 2017
  end-page: 322
  article-title: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
  publication-title: Lancet Oncol
  contributor:
    fullname: Siefker-Radtke
– volume: 8
  start-page: 38056
  year: 2017
  end-page: 38060
  article-title: Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
  publication-title: Oncotarget
  contributor:
    fullname: Delaunay
– volume: 47
  start-page: 257
  year: 2015
  end-page: 262
  article-title: Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers
  publication-title: Nat Genet
  contributor:
    fullname: de Borja
– volume: 21
  start-page: 75
  year: 2020
  end-page: 85
  article-title: Blood predictive biomarkers for patients with non-small-cell lung cancer associated with clinical response to nivolumab
  publication-title: Clin Lung Cancer
  contributor:
    fullname: Ponce
– volume: 378
  start-page: 2093
  year: 2018
  end-page: 2104
  article-title: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
  publication-title: N Engl J Med
  contributor:
    fullname: Pluzanski
– volume: 3
  start-page: 39
  year: 2015
  article-title: Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
  publication-title: J Immunother Cancer
  contributor:
    fullname: Lin
– volume: 387
  start-page: 1837
  year: 2016
  end-page: 1846
  article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
  publication-title: Lancet
  contributor:
    fullname: Ballinger
– volume: 12
  start-page: 458
  year: 2017
  end-page: 466
  article-title: Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases
  publication-title: J Thorac Oncol
  contributor:
    fullname: Huynh
– volume: 97
  start-page: 59
  year: 2018
  end-page: 61
  article-title: CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
  publication-title: Eur J Cancer
  contributor:
    fullname: Morabito
– volume: 144
  start-page: 1170
  year: 2019
  end-page: 1179
  article-title: Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor
  publication-title: Int J Cancer
  contributor:
    fullname: Hattori
– volume: 28
  start-page: 1988
  year: 2017
  end-page: 1995
  article-title: Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
  publication-title: Ann Oncol
  contributor:
    fullname: Schalper
– volume: 67
  start-page: 1471
  year: 2018
  end-page: 1480
  article-title: Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors
  publication-title: Diabetes
  contributor:
    fullname: Perdigoto
– volume: 22
  start-page: 5487
  year: 2016
  end-page: 5496
  article-title: Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab
  publication-title: Clin Cancer Res
  contributor:
    fullname: Hassel
– volume: 2021
  start-page: 6639366
  year: 2021
  article-title: Hyperprogressive disease caused by PD-1 inhibitors for the treatment of pan-cancer
  publication-title: Dis Markers
  contributor:
    fullname: Yan
– volume: 123
  start-page: 965
  year: 2020
  end-page: 972
  article-title: Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
  publication-title: Br J Cancer
  contributor:
    fullname: Kawabata
– volume: 4
  start-page: 717
  year: 2018
  end-page: 721
  article-title: Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies
  publication-title: JAMA Oncol
  contributor:
    fullname: Menzies
– volume: 9
  start-page: 15542
  year: 2018
  end-page: 15551
  article-title: Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
  publication-title: Oncotarget
  contributor:
    fullname: Tanita
– volume: 9
  start-page: 14039
  year: 2019
  article-title: Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
  publication-title: Sci Rep
  contributor:
    fullname: Sun
– volume: 5
  start-page: 95
  year: 2017
  article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
  publication-title: J Immunother Cancer
  contributor:
    fullname: Abdallah
– volume: 10
  start-page: 2509
  year: 2021
  end-page: 2522
  article-title: Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
  publication-title: Transl Lung Cancer Res
  contributor:
    fullname: Molina-Pinelo
– volume: 10
  year: 2020
  article-title: Hyperprogression: a novel response pattern under immunotherapy
  publication-title: Clin Transl Med
  contributor:
    fullname: Xiao
– volume: 11
  start-page: 955
  year: 2018
  end-page: 965
  article-title: Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
  publication-title: Onco Targets Ther
  contributor:
    fullname: Sacdalan
– volume: 9
  year: 2021
  article-title: Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
  publication-title: J Immunother Cancer
  contributor:
    fullname: Choi
– volume: 22
  start-page: 813
  year: 2016
  end-page: 820
  article-title: Microsatellite instability as a biomarker for PD-1 blockade
  publication-title: Clin Cancer Res
  contributor:
    fullname: Le
– volume: 7
  start-page: 675
  year: 2017
  end-page: 693
  article-title: DNA damage and repair biomarkers of immunotherapy response
  publication-title: Cancer Discov
  contributor:
    fullname: Konstantinopoulos
– volume: 37
  start-page: 1560
  year: 2015
  end-page: 1571
  article-title: Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis
  publication-title: Cell Physiol Biochem
  contributor:
    fullname: He
– volume: 17
  start-page: 407
  year: 2016
  end-page: 413
  article-title: PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
  publication-title: Cancer Biol Ther
  contributor:
    fullname: Li
– volume: 12
  start-page: 786046
  year: 2021
  article-title: Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy
  publication-title: Front Immunol
  contributor:
    fullname: Johnson
– volume: 150
  start-page: 76
  year: 2020
  end-page: 82
  article-title: Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
  publication-title: Lung Cancer
  contributor:
    fullname: Zhou
– volume: 19
  start-page: 75
  year: 2022
  end-page: 90
  article-title: Tumour burden and efficacy of immune-checkpoint inhibitors
  publication-title: Nat Rev Clin Oncol
  contributor:
    fullname: Caramella
– volume: 168
  start-page: 121
  year: 2018
  end-page: 130
  article-title: Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review
  publication-title: Ann Intern Med
  contributor:
    fullname: Lopez-Olivo
– volume: 378
  start-page: 158
  year: 2018
  end-page: 168
  article-title: Immune-related adverse events associated with immune checkpoint blockade
  publication-title: N Engl J Med
  contributor:
    fullname: Hellmann
– volume: 46
  start-page: 260
  year: 2018
  end-page: 264
  article-title: (18)F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer
  publication-title: J Nucl Med Technol
  contributor:
    fullname: Nia
– volume: 36
  start-page: 601
  year: 2018
  end-page: 607
  article-title: Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
  publication-title: Invest New Drugs
  contributor:
    fullname: Bilen
– volume: 9
  start-page: 13404
  year: 2019
  article-title: HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
  publication-title: Sci Rep
  contributor:
    fullname: Zeng
– volume: 19
  start-page: 1579
  year: 2018
  end-page: 1589
  article-title: Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
  publication-title: Lancet Oncol
  contributor:
    fullname: Moey
– volume: 16
  start-page: 1909
  year: 2021
  end-page: 1924
  article-title: IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC
  publication-title: J Thorac Oncol
  contributor:
    fullname: Jotte
– volume: 541
  start-page: 321
  year: 2017
  end-page: 330
  article-title: Elements of cancer immunity and the cancer-immune set point
  publication-title: Nature
  contributor:
    fullname: Mellman
– volume: 7
  start-page: 193
  year: 2019
  article-title: Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
  publication-title: J Immunother Cancer
  contributor:
    fullname: Tu
– volume: 5
  start-page: 376
  year: 2019
  end-page: 383
  article-title: Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer
  publication-title: JAMA Oncol
  contributor:
    fullname: Sugisaka
– volume: 515
  start-page: 568
  year: 2014
  end-page: 571
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  contributor:
    fullname: Yearley
– volume: 120
  start-page: 63
  year: 2019
  end-page: 68
  article-title: Immune dysregulation in cancer patients developing immune-related adverse events
  publication-title: Br J Cancer
  contributor:
    fullname: Luo
– volume: 20
  start-page: 101375
  year: 2022
  article-title: The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: a meta-analysis and bioinformatics analysis
  publication-title: Transl Oncol
  contributor:
    fullname: Chen
– volume: 86
  start-page: 71
  year: 2017
  end-page: 73
  article-title: Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab reactivity
  publication-title: J Dermatol Sci
  contributor:
    fullname: Okune
– volume: 99
  start-page: 256
  year: 2021
  end-page: 259
  article-title: The risk factors associated with immune checkpoint inhibitor-related pneumonitis
  publication-title: Oncology
  contributor:
    fullname: Niimura
– volume: 23
  start-page: 4242
  year: 2017
  end-page: 4250
  article-title: Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate
  publication-title: Clin Cancer Res
  contributor:
    fullname: Walavalkar
– volume: 37
  start-page: 992
  year: 2019
  end-page: 1000
  article-title: First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
  publication-title: J Clin Oncol
  contributor:
    fullname: Awad
– volume: 11
  start-page: 2793
  year: 2020
  end-page: 2803
  article-title: Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors
  publication-title: Thorac Cancer
  contributor:
    fullname: Kim
– volume: 11
  start-page: 9029
  year: 2021
  article-title: Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
  publication-title: Sci Rep
  contributor:
    fullname: Morelli
– volume: 7
  start-page: 77404
  year: 2016
  end-page: 77415
  article-title: Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
  publication-title: Oncotarget
  contributor:
    fullname: Takahashi
– volume: 31
  start-page: 525
  year: 2020
  end-page: 531
  article-title: Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
  publication-title: Ann Oncol
  contributor:
    fullname: Nagarkar
– volume: 18
  start-page: 31
  year: 2017
  end-page: 41
  article-title: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
  publication-title: Lancet Oncol
  contributor:
    fullname: Goldman
– volume: 357
  start-page: 409
  year: 2017
  end-page: 413
  article-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  publication-title: Science
  contributor:
    fullname: Smith
– volume: 16
  start-page: 94
  year: 2018
  article-title: Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
  publication-title: J Transl Med
  contributor:
    fullname: Campana
– volume: 8
  start-page: 72755
  year: 2017
  end-page: 72772
  article-title: Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
  publication-title: Oncotarget
  contributor:
    fullname: Pachmann
– volume: 369
  start-page: 936
  year: 2020
  end-page: 942
  article-title: Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage
  publication-title: Science
  contributor:
    fullname: Sassi
– volume: 23
  start-page: 172
  year: 2022
  end-page: 184
  article-title: HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
  publication-title: Lancet Oncol
  contributor:
    fullname: Dean
– volume: 29
  start-page: 953
  year: 2018
  end-page: 958
  article-title: Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
  publication-title: Ann Oncol
  contributor:
    fullname: Rouquette
– volume: 32
  start-page: 1391
  year: 2021
  end-page: 1399
  article-title: Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
  publication-title: Ann Oncol
  contributor:
    fullname: Facchinetti
– volume: 7
  start-page: 690
  year: 2018
  end-page: 697
  article-title: Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
  publication-title: Cancer Med
  contributor:
    fullname: Shoushtari
– volume: 13
  start-page: 286
  year: 2021
  article-title: Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC)
  publication-title: Cancers (Basel)
  contributor:
    fullname: Papaxoinis
– volume: 3
  start-page: 1051
  year: 2017
  end-page: 1058
  article-title: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer
  publication-title: JAMA Oncol
  contributor:
    fullname: Taube
– volume: 92
  start-page: 102134
  year: 2021
  article-title: Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors–a systematic review and meta-analysis
  publication-title: Cancer Treat Rev
  contributor:
    fullname: Boldt
– volume: 8
  start-page: 1243
  year: 2020
  end-page: 1250
  article-title: The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer
  publication-title: Cancer Immunol Res
  contributor:
    fullname: Elkrief
– volume: 128
  start-page: 715
  year: 2018
  end-page: 720
  article-title: Early B cell changes predict autoimmunity following combination immune checkpoint blockade
  publication-title: J Clin Invest
  contributor:
    fullname: Ferreira
– volume: 487
  start-page: 330
  year: 2012
  end-page: 337
  article-title: Comprehensive molecular characterization of human colon and rectal cancer
  publication-title: Nature
– volume: 11
  start-page: 1618
  year: 2020
  end-page: 1628
  article-title: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
  publication-title: Oncotarget
  contributor:
    fullname: Crozes
– volume: 12
  start-page: 10559
  year: 2019
  end-page: 10568
  article-title: Pseudo-progression and the neutrophil-to-lymphocyte ratio in non-small cell lung cancer treated with immune checkpoint inhibitors: a case-control study
  publication-title: Onco Targets Ther
  contributor:
    fullname: Nagano
– volume: 27
  start-page: 1336
  year: 2017
  end-page: 1343
  article-title: Human mismatch repair system balances mutation rates between strands by removing more mismatches from the lagging strand
  publication-title: Genome Res
  contributor:
    fullname: Nikolaev
– volume: 12
  start-page: 665133
  year: 2021
  article-title: Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients
  publication-title: Front Immunol
  contributor:
    fullname: Gu
– ident: bibr93-17588359231163807
  doi: 10.1016/j.jdermsci.2016.12.019
– ident: bibr5-17588359231163807
  doi: 10.1001/jamaoncol.2017.0013
– volume-title: 2022 ASCO Annual Meeting I
  year: 2022
  ident: bibr108-17588359231163807
  contributor:
    fullname: Ghasemi Saghand P
– volume-title: 2022 ASCO Annual Meeting I
  year: 2022
  ident: bibr45-17588359231163807
  contributor:
    fullname: Grohe C
– ident: bibr98-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2558
– ident: bibr103-17588359231163807
  doi: 10.1002/cam4.1356
– ident: bibr101-17588359231163807
  doi: 10.1016/j.cllc.2019.08.006
– ident: bibr10-17588359231163807
  doi: 10.1056/NEJMc1713444
– ident: bibr68-17588359231163807
  doi: 10.1007/s10637-017-0524-2
– ident: bibr67-17588359231163807
  doi: 10.2967/jnmt.117.204933
– ident: bibr74-17588359231163807
  doi: 10.1158/1078-0432.CCR-16-0127
– ident: bibr4-17588359231163807
  doi: 10.1093/annonc/mdy014
– ident: bibr37-17588359231163807
  doi: 10.1016/S1470-2045(21)00582-9
– ident: bibr50-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2598
– ident: bibr13-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.9048
– ident: bibr64-17588359231163807
  doi: 10.1038/s41598-019-49771-0
– ident: bibr95-17588359231163807
  doi: 10.18632/oncotarget.24509
– ident: bibr14-17588359231163807
  doi: 10.1016/j.tranon.2022.101375
– ident: bibr21-17588359231163807
  doi: 10.1038/ng.3202
– ident: bibr43-17588359231163807
  doi: 10.1016/j.annonc.2020.01.006
– ident: bibr54-17588359231163807
  doi: 10.3390/cancers13020286
– ident: bibr77-17588359231163807
  doi: 10.18632/oncotarget.27563
– ident: bibr80-17588359231163807
  doi: 10.1016/j.lungcan.2020.08.015
– ident: bibr58-17588359231163807
  doi: 10.1056/NEJMra1703481
– ident: bibr12-17588359231163807
  doi: 10.1200/JCO.18.01042
– ident: bibr105-17588359231163807
  doi: 10.1155/2021/6639366
– ident: bibr106-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.9064
– ident: bibr55-17588359231163807
  doi: 10.1136/jitc-2020-001935
– ident: bibr19-17588359231163807
  doi: 10.1158/2159-8290.CD-17-0226
– ident: bibr109-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2626
– ident: bibr6-17588359231163807
  doi: 10.1016/j.jtho.2016.10.015
– ident: bibr66-17588359231163807
  doi: 10.1200/JCO.2018.79.0006
– ident: bibr3-17588359231163807
  doi: 10.1016/j.cllc.2016.03.003
– ident: bibr42-17588359231163807
  doi: 10.1093/annonc/mdx108
– ident: bibr7-17588359231163807
  doi: 10.3389/fimmu.2021.665133
– ident: bibr24-17588359231163807
  doi: 10.1136/jitc-2021-002797
– ident: bibr38-17588359231163807
  doi: 10.1126/science.aao4572
– ident: bibr65-17588359231163807
  doi: 10.1038/s41591-018-0101-z
– ident: bibr8-17588359231163807
  doi: 10.18632/oncotarget.20346
– ident: bibr11-17588359231163807
  doi: 10.1056/NEJMoa1801946
– ident: bibr1-17588359231163807
  doi: 10.1056/NEJMoa1501824
– ident: bibr15-17588359231163807
  doi: 10.1158/1078-0432.CCR-15-1678
– ident: bibr71-17588359231163807
  doi: 10.2147/OTT.S153290
– ident: bibr23-17588359231163807
  doi: 10.1001/jamaoncol.2015.2151
– ident: bibr49-17588359231163807
  doi: 10.1002/ctm2.167
– ident: bibr78-17588359231163807
  doi: 10.1186/s12885-020-07727-y
– ident: bibr94-17588359231163807
  doi: 10.1186/s40425-015-0081-1
– ident: bibr44-17588359231163807
  doi: 10.1016/j.annonc.2021.08.1744
– ident: bibr90-17588359231163807
  doi: 10.1186/s12967-018-1467-x
– ident: bibr97-17588359231163807
  doi: 10.1038/s41467-020-18742-9
– ident: bibr87-17588359231163807
  doi: 10.1016/S1470-2045(17)30065-7
– ident: bibr72-17588359231163807
  doi: 10.18632/oncotarget.12677
– ident: bibr29-17588359231163807
  doi: 10.1038/s41416-018-0074-1
– ident: bibr57-17588359231163807
  doi: 10.3389/fimmu.2021.786046
– ident: bibr2-17588359231163807
  doi: 10.1016/S1470-2045(16)30624-6
– ident: bibr73-17588359231163807
  doi: 10.21037/tlcr-21-156
– ident: bibr56-17588359231163807
  doi: 10.1159/000512633
– ident: bibr22-17588359231163807
  doi: 10.1101/gr.219915.116
– ident: bibr61-17588359231163807
  doi: 10.1038/s41598-021-88307-3
– ident: bibr69-17588359231163807
  doi: 10.1016/j.lungcan.2019.02.009
– ident: bibr76-17588359231163807
  doi: 10.1111/cei.13505
– ident: bibr53-17588359231163807
  doi: 10.1111/1759-7714.13594
– ident: bibr9-17588359231163807
  doi: 10.1038/s41571-021-00564-3
– ident: bibr40-17588359231163807
  doi: 10.1186/s40425-019-0650-9
– ident: bibr111-17588359231163807
  doi: 10.1016/j.ctrv.2020.102134
– ident: bibr34-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2662
– ident: bibr100-17588359231163807
  doi: 10.1001/jamaoncol.2017.4771
– ident: bibr25-17588359231163807
  doi: 10.1093/jnci/djv303
– ident: bibr83-17588359231163807
  doi: 10.18632/oncotarget.16935
– ident: bibr102-17588359231163807
  doi: 10.1056/NEJMoa1412082
– ident: bibr20-17588359231163807
  doi: 10.1016/j.cell.2016.02.065
– ident: bibr51-17588359231163807
  doi: 10.1016/j.biopha.2022.112949
– ident: bibr89-17588359231163807
  doi: 10.1093/annonc/mdx190
– ident: bibr47-17588359231163807
  doi: 10.2967/jnumed.119.237768
– ident: bibr28-17588359231163807
  doi: 10.1016/j.ejca.2018.04.005
– ident: bibr63-17588359231163807
  doi: 10.1001/jamaoncol.2018.5860
– ident: bibr92-17588359231163807
  doi: 10.1038/s41416-018-0155-1
– ident: bibr16-17588359231163807
  doi: 10.1371/journal.pone.0015661
– ident: bibr96-17588359231163807
  doi: 10.1172/JCI96798
– ident: bibr41-17588359231163807
  doi: 10.1158/2326-6066.CIR-20-0196
– ident: bibr110-17588359231163807
  doi: 10.21037/tlcr-22-171
– ident: bibr32-17588359231163807
  doi: 10.1038/nature21349
– ident: bibr27-17588359231163807
  doi: 10.1016/j.jtho.2019.01.011
– ident: bibr86-17588359231163807
  doi: 10.1016/S0140-6736(16)00587-0
– ident: bibr91-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2549
– ident: bibr99-17588359231163807
  doi: 10.1002/ijc.31923
– ident: bibr104-17588359231163807
  doi: 10.1007/s00262-020-02716-3
– ident: bibr35-17588359231163807
  doi: 10.1038/nature13954
– ident: bibr18-17588359231163807
  doi: 10.1126/science.aan6733
– ident: bibr84-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2550
– ident: bibr81-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2544
– ident: bibr85-17588359231163807
  doi: 10.1158/1078-0432.CCR-17-0231
– ident: bibr48-17588359231163807
  doi: 10.1038/s41416-020-0975-7
– ident: bibr107-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.9066
– ident: bibr46-17588359231163807
  doi: 10.21037/tlcr-21-575
– ident: bibr59-17588359231163807
  doi: 10.1186/s40425-017-0300-z
– ident: bibr75-17588359231163807
  doi: 10.2147/OTT.S228138
– ident: bibr112-17588359231163807
  doi: 10.1186/s12916-020-01549-2
– ident: bibr30-17588359231163807
  doi: 10.1158/1078-0432.CCR-16-3133
– ident: bibr79-17588359231163807
  doi: 10.1038/s41598-019-50574-6
– ident: bibr88-17588359231163807
  doi: 10.1016/j.jtho.2021.07.009
– ident: bibr36-17588359231163807
  doi: 10.1200/JCO.2022.40.16_suppl.2596
– ident: bibr17-17588359231163807
  doi: 10.1038/nature11252
– ident: bibr33-17588359231163807
  doi: 10.1159/000438523
– ident: bibr70-17588359231163807
  doi: 10.1016/S1470-2045(18)30608-9
– ident: bibr60-17588359231163807
  doi: 10.7326/M17-2073
– ident: bibr62-17588359231163807
  doi: 10.2337/dbi18-0002
– ident: bibr26-17588359231163807
  doi: 10.1080/15384047.2016.1156256
– ident: bibr39-17588359231163807
  doi: 10.1126/science.aax0701
– ident: bibr82-17588359231163807
  doi: 10.1001/jamaoncol.2017.5332
– ident: bibr52-17588359231163807
  doi: 10.1007/s00432-020-03316-5
– ident: bibr31-17588359231163807
  doi: 10.1186/s12943-020-01200-x
SSID ssj0066460
Score 2.320537
SecondaryResourceType review_article
Snippet Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 17588359231163807
SubjectTerms Artificial intelligence
Biomarkers
Cancer
Cancer immunotherapy
Genomic Biomarkers in Cancer Immunotherapy
Immune checkpoint inhibitors
Malignancy
Patients
Peripheral blood
Solid tumors
Toxicity
Tumor microenvironment
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB5kD-JFfFtdJYIgCMW0Sdv0qIsigp4UvJXmhV5aWbvg_ntn2u66i4oXj21DGWaSzDfJzDcApy7jxPkoQl7mOkR_rEKdGBMK9G42K61Qno4G7h_S2yd595w8L7T6opywjh64U9yFi3HDFJLbnLCzNtpFeZkSjb9R6G1Mu_vyfBZMdXtwmsp0dodJ9EroIxVCDQIzhD-od-yCF2rJ-n9CmN8TJReyvVoHdLMB6z1yZJedxJuw4qotWL3v78a3wY2o0UaX2sZqz95wL-vLHllZWTZ_oIp7SsoZvzM6hWWOWCRKM21HNfUH_q-Z0h8MzYgxe6USkr5Qa7oDTzfXj6PbsG-iEBqpkibUMheeql2VN6k1SnvUZOS8s9KjmjSGKz6xrtRSpYkTnGsnhfRR7rnGxazELgyqunL7wHB0lFqpbOSExLiltHGic-2SjLeWCeB8ptTirePKKKKeTvybBQK4IrXPBxLNdfsCjV_0xi_-Mn4Aw5nRin7tvRfUfwujXoQuAZzMP-OqoauQsnL1BMegBDm1OI4D2OtsPJdEZFEkMiEDUEvWXxJ1-Uv1-tIycxNZGsaDPIAzmihfMv2qhoP_UMMhrMWIvbqToSEMmvHEHSFWavRxuyw-AUL_DVY
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS-QwEB88BbkX0Tv16seRA-FACLabtE2fROVEDrwnhX0rzZf60u7tVnD_e2fabHXx47FpSKeZJPORmd8AHLk8JsxHweOq0BzlseI6NYYLlG42r6xQnlwD1_-yq1v5d5yOg8NtFsIqF2did1DbxpCP_ISqKqEtgwLpdPKfU9Uoul0NJTS-wFoyijMK6crHg8GVZbLPEkadmCshF7eaBLhEbah8kHpDGglVk30llzr4_vd0zrehk6_ivzqRdLkJG0GXZGc987dgxdXfYP063JZ_B3dBpTf6YDfWeDbB0y0kQrKqtmx4oBx8CtOZzhj5ZZkjXInKzLtebfOE47VzGsHQGpmyB0oqCalb8224vfxzc3HFQ1kFbqRKW65lITzlvypvMmuU9hZPPOedlR6nTKMB41PrKi1VljoRx9pJIX1S-Fjj9lZiB1brpnY_gGHvJLNS2cQJiZZMZUepLrRL81gKbXQEx4tJLSc9ekaZBIDxNxyI4JymfehIwNddQzO9K8M-Kt0I5SeyEknOu0-4pKgyqupgFCofJoKDBdPKsBtn5cvaieDX8Br3EV2OVLVrHrEPUlBQ0eNRBLs9jwdKRJ4kIhcyArXE_SVSl9_UD_cdVjfBp6GFGEfwmxbKC00fTsPe53-wD1-p4n3vBTqA1Xb66A5RL2r1z27xPwPdCgfI
  priority: 102
  providerName: ProQuest
– databaseName: SAGE Open Access
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3LatwwcEg3UNpT06ebByoUCgU18kq25VNJQpZQSA8lobkZ69XkEDtsvND9-8zY8rZLEsjR9mANI81D8wT47AtBPR8lF3VpOOpjzU1mLZeo3VxRO6kDuQZOf-Yn5-rHRXaxAe1YCxMpePuN0qoQo15YE3eTN3o_Bhn3UedpNB3IOCF7QhTfF911Nbi7x6ka9Ibi04trCm1bSohc8rG87RlsIqsWegKbB7Nfv89G4Z3naigsxgU4rRADoQ8uuqbK-o7_D5mp97Mt_0sZ67XY7BW8pMoGNoQDtmDDN6_h-WkMrr8Bf0STOobcONYGdoPCMNZNsrpxbPVAJfuU1TO_ZeTGZZ7aUNR22UN17V_8X7ekP1g6UnN2RTUosdJr-RbOZ8dnRyc8TmHgVums40aVMlC5rA42d1ab4FBA-uCdCkgug_edkDlfG6XzzEshjFdShbQMwqA00PIdTJq28R-AIXSaO6Vd6qXCi0_tppkpjc8KoaSxJoGvI0Grm6HZRpXGfuT3qJ_AIZF8BUh9svsX7fxPFdmu8lNUt1IJRLnol_BpWec0BMJqtFVsAjvjhlXj0atogBdem9H2SeDT6jOyHcVS6sa3C4RBDEqakTxN4P2wvytMZJGmspAqAb2282uorn9pri771t7UbQ0vlCKBL3RI_uH0KBk-PhlyG15M0UIb_Ec7MOnmC7-LFlVn9iIX3AEWLRnp
  priority: 102
  providerName: SAGE Publications
Title Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy
URI https://journals.sagepub.com/doi/full/10.1177/17588359231163807
https://www.ncbi.nlm.nih.gov/pubmed/37113734
https://www.proquest.com/docview/2920549181
https://search.proquest.com/docview/2807910572
https://pubmed.ncbi.nlm.nih.gov/PMC10126660
https://doaj.org/article/e2299340d91743bcbe19a65000c8381c
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZeSvdZb11QoTAouLEj2ZYf29BQBimltDRvxvraAqsdUheW_353sp02dHvZk7El5EN3p_tJug-AI5tFlPORh1GZqxDtsQxVonXI0bqZrDRcOjoamF6mF7fi-yyZbUHax8J4p32t5ifVr_uTav7T-1Yu7vWw9xMbXk3HlJMKYXc03IZtlNB-j96uv2kq2thgRMKh5KK_y6Q0S_QNIQeBGsIhVEP2mTXySfv_hjRfOkw-8_ryhmiyB7sdgmSnLaVvYctW7-D1tLsjfw92TAU3Whc3Vju2wDWtC39kZWXY-oUi78k5Z_nA6DSWWcomUeqV79XUv3G8ZkUjaJKMJZtTKEkXsLX6ALeT85vxRdgVUwi1kEkTKpFzR1Gv0unUaKmcwXXOOmuEwylTuG1xibGlEjJNLI8iZQUXLs5dpFCpJf8IO1Vd2X1g2DtOjZAmtlzg_qU0o0TlyiZZJLjSKoDjflKLRZszo4i7tOIvOBDAGU37uiOlu_Yf6uWPomN6YUdoNZGVSHLmf2HjvEyploOWCDl0AAc904pOBx8KqsOFu1-EMAEcrptRe-hKpKxs_Yh9kIKcSh2PAvjU8nhNCc_imGdcBCA3uL9B6mYLCqzP0N0LaADfSFCeaPrnNHz-_598gTcjRF7tudAB7DTLR_sVkVKjBqges2wAr04n13c3-Dw7v7y6Hvhzh4FXmj9HsxR4
link.rule.ids 230,314,315,730,783,787,795,867,888,2109,12068,21400,21978,27865,27934,27936,27937,31731,31732,33756,33757,43322,43817,44957,45345,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9RAEJ8gJOKLERWtAq6JiYnJxvZ2226fjBDICRxPkNxb0_1SXtrzriTcf89Mu1e4ID623bTTnZ2dj535DcAXl8eE-Sh4XBWaoz5WXKfGcIHazeaVFcpTaGBykY2v5Ok0nYaA2yKkVa72xG6jto2hGPl36qqEvgwqpB-zv5y6RtHpamih8Qy2CIeLOhjk08HhyjLZVwmjTcyVkKtTTQJcontofJB5QxYJdZN9oJc6-P5_2ZyPUycf5H91KunkFbwMtiT72TN_BzZc_RqeT8Jp-RtwR9R6o092Y41nM9zdQiEkq2rLhguqwac0nfmCUVyWOcKVqMyyG9U2t_i-dklvMLRG5uyaikpC6dbyLVydHF8ejXloq8CNVGnLtSyEp_pX5U1mjdLe4o7nvLPS45RpdGB8al2lpcpSJ-JYOymkTwofaxRvJXZhs25q9x4Yjk4yK5VNnJDoyVR2lOpCuzSPpdBGR_BtNanlrEfPKJMAMP6IAxEc0rQPAwn4urvRzH-XQY5KN0L9iaxEkvPuEy4pqoy6OhiFxoeJYG_FtDJI46K8XzsRfB4eoxzR4UhVu-YGxyAFBTU9HkXwrufxQInIk0TkQkag1ri_Rur6k_r6T4fVTfBp6CHGEXylhXJP05PT8OH_f_AJtseXk_Py_NfF2Ud4MUKbq48I7cFmO79x-2gjtfqgE4Q7U4gKrw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1rS9xAcCgeSP2k9mH01BUKhUJqcrtJNh-telhfiCj1W8i-9L4kxxnB-_fOJHvXHir0Y5LZzTC7s_PYeQB8s1lENR95GJW5ClEey1AlWoccpZvJSsOlI9fAxWV6citO75I773CjXBhPwcefFFaFGLWHNXH32Lh9f8e4jyJPouZAugmpE5RM3hOo6aPx1TsYXv-5mZ3FaSq6PGEcENIIf6_55iQLkqkt4P-W1vk6ePKfCLBWKA1XYYUSFVjn3V-DD7Zah-ULf1f-CewhNd7oQt1Y7dgYzzafBsnKyrD5A2XgU5DO5JGRV5ZZqipR6mkL1dTPOF8zpRk07ZAJG1FKiU_cmn6G2-HxzeFJ6JsqhFrIpAmVyLmj7FfpdGq0VM7geWedNcIhuRSaLy4xtlRCponlUaSs4MLFuYsUMrfkX2Cpqiu7AQyh49QIaWLLBdoxpRkkKlc2ySLBlVYB_JgRtBh3tTOK2JcXf0X9AH4RyeeAVPa6fVFP7gvPRYUdoPTkIkKUs_YXNs7LlHo6aImqhw6gP1uwYraTCurHhVYwqjIB7M0_IxfR1UhZ2foJYRCDnFoeDwL42q3vHBOexTHPuAhALqz8AqqLX6rRQ1upm4qnoX0YBfCdNslfnN4lw-Z_Q-7C8tXRsDj_fXm2BR8HqHt1nqE-LDWTJ7uNulKjdjxDvAB2Kwhl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Correlation+of+preclinical+and+clinical+biomarkers+with+efficacy+and+toxicity+of+cancer+immunotherapy&rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&rft.au=Zheng%2C+Lin-Peng&rft.au=Yang%2C+Jing&rft.au=Chen%2C+Xie-Wan&rft.au=Li%2C+Ling-Chen&rft.date=2023-01-01&rft.pub=SAGE+Publications&rft.issn=1758-8359&rft.eissn=1758-8359&rft.volume=15&rft_id=info:doi/10.1177%2F17588359231163807&rft.externalDocID=10.1177_17588359231163807
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-8359&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-8359&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-8359&client=summon